CA3099196A1 - Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition - Google Patents
Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition Download PDFInfo
- Publication number
- CA3099196A1 CA3099196A1 CA3099196A CA3099196A CA3099196A1 CA 3099196 A1 CA3099196 A1 CA 3099196A1 CA 3099196 A CA3099196 A CA 3099196A CA 3099196 A CA3099196 A CA 3099196A CA 3099196 A1 CA3099196 A1 CA 3099196A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound represented
- crystal form
- maleate
- present application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (zh) | 2018-05-04 | 2018-05-04 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3099196A1 true CA3099196A1 (en) | 2019-11-07 |
Family
ID=68387039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3099196A Pending CA3099196A1 (en) | 2018-05-04 | 2018-05-04 | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11512078B2 (https=) |
| EP (2) | EP4353719B1 (https=) |
| JP (3) | JP7275253B2 (https=) |
| KR (2) | KR20240094023A (https=) |
| AU (1) | AU2018421487B2 (https=) |
| CA (1) | CA3099196A1 (https=) |
| ES (1) | ES2978392T3 (https=) |
| IL (3) | IL312512B2 (https=) |
| MX (1) | MX2020011665A (https=) |
| NZ (1) | NZ770323A (https=) |
| SG (1) | SG11202010969UA (https=) |
| WO (1) | WO2019210511A1 (https=) |
| ZA (1) | ZA202007347B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ770323A (en) * | 2018-05-04 | 2025-12-19 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
| WO2022099155A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN103450171B (zh) | 2013-09-22 | 2015-07-08 | 苏州康乃德生物医药有限公司 | 一种免疫调节化合物、其用途和包含其的药物组合物 |
| CN105315266B (zh) * | 2014-08-01 | 2019-10-01 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
| CN105348276B (zh) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 |
| CN112778290B (zh) | 2017-01-11 | 2022-12-06 | 苏州康乃德生物医药有限公司 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
| NZ770323A (en) * | 2018-05-04 | 2025-12-19 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
-
2018
- 2018-05-04 NZ NZ770323A patent/NZ770323A/en unknown
- 2018-05-04 ES ES18917186T patent/ES2978392T3/es active Active
- 2018-05-04 AU AU2018421487A patent/AU2018421487B2/en active Active
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/zh not_active Ceased
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/ja active Active
- 2018-05-04 KR KR1020247018420A patent/KR20240094023A/ko active Pending
- 2018-05-04 IL IL312512A patent/IL312512B2/en unknown
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 EP EP24155906.1A patent/EP4353719B1/en active Active
- 2018-05-04 IL IL278464A patent/IL278464B2/en unknown
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 KR KR1020207034174A patent/KR102672632B1/ko active Active
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/es unknown
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US12202822B2/en active Active
-
2023
- 2023-02-17 JP JP2023023091A patent/JP7651198B2/ja active Active
-
2024
- 2024-12-11 US US18/977,539 patent/US20250320200A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035420A patent/JP2025074350A/ja active Pending
- 2025-09-29 IL IL323665A patent/IL323665A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250320200A1 (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| US11286259B2 (en) | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof | |
| CN105229001B (zh) | 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途 | |
| CN112778290B (zh) | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 | |
| CN105461610B (zh) | 一种阿普斯特的晶型及其制备方法、药物组合物和用途 | |
| CN106928228B (zh) | 奥格列汀盐及其晶型、它们的制备方法和药物组合物 | |
| HK40106546A (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| RU2822288C2 (ru) | Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе | |
| HK40106546B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| HK40042284B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| HK40042284A (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| JP2018510173A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
| BR112020022429B1 (pt) | Forma cristalina do maleato de agonista de receptor s1p1, seu método de preparação, seu uso e composição farmacêutica que o compreende | |
| BR122022025339B1 (pt) | Sulfato de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1 | |
| BR122022025293B1 (pt) | Sal de sódio de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241021 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250110 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250407 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250515 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250515 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251029 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |